GLP-1 receptor agonists show strong cardiovascular protection: meta-analysis confirms tirzepatide and semaglutide reduce heart attacks, strokes and cardiovascular death
A 2025 meta-analysis adds to a growing body of evidence that GLP-1 receptor agonists — including tirzepatide and semaglutide — deliver significant cardiovascular benefits beyond weight loss and glycaemic control.
FDA approves oral semaglutide (Wegovy pill): first oral GLP-1 receptor agonist licensed for weight management
The US FDA has approved Novo Nordisk's oral semaglutide formulation of Wegovy, making it the first oral GLP-1 receptor agonist licensed for chronic weight management. The decision expands peptide-based obesity therapy beyond injectable delivery.
CagriSema REDEFINE-2 Phase 3: Novo Nordisk's dual amylin/GLP-1 combination shows superior weight loss in type 2 diabetes
Novo Nordisk reports that CagriSema (cagrilintide + semaglutide) achieved superior weight loss in adults with obesity or overweight and type 2 diabetes, building on the REDEFINE-1 obesity data.
Orforglipron ACHIEVE-3 and ACHIEVE-4 Phase 3: oral GLP-1 agonist demonstrates superior glycemic control in type 2 diabetes
Eli Lilly reports two successful Phase 3 trials showing orforglipron's potential as a foundational oral treatment for type 2 diabetes, strengthening its case beyond obesity.
FDA approves semaglutide for MASH liver disease: first GLP-1 agonist licensed for metabolic-associated steatohepatitis in the US
The FDA has approved semaglutide (Wegovy) for the treatment of metabolic-associated steatohepatitis (MASH), marking the first GLP-1 receptor agonist licensed for this serious liver condition.
Amgen reports positive topline results from first MariTide Phase 3 obesity trial
Maridebart cafraglutide (MariTide), Amgen's investigational monthly GIP receptor antagonist/GLP-1 receptor agonist, achieves positive topline results in its first Phase 3 obesity study — advancing the next generation of long-acting incretin therapeutics.
MHRA approves semaglutide (Wegovy) for metabolic-associated steatohepatitis (MASH): first GLP-1 agonist licensed for liver disease in the UK
The UK regulator has granted conditional approval for semaglutide to treat MASH in adults with moderate-to-advanced liver fibrosis — the first GLP-1 receptor agonist licensed for a liver disease indication in the UK.
MHRA strengthens warnings on acute pancreatitis risk with GLP-1 and dual GIP/GLP-1 receptor agonists
UK regulator updates drug safety guidance after reports of necrotising and fatal pancreatitis cases associated with GLP-1 receptor agonist therapies
MHRA reiterates GLP-1 receptor agonists are prescription-only medicines and targets improper supply channels
The UK regulator has reiterated that GLP-1 receptor agonists are prescription-only medicines and signalled enforcement against improper online supply — here is what it means for peptide researchers.
FDA proposes permanently excluding semaglutide, tirzepatide and liraglutide from 503B bulks list: compounding of GLP-1 peptides faces definitive end
The FDA's proposal to remove three major GLP-1 agonists from the 503B Bulks List would permanently end large-scale compounding of semaglutide, tirzepatide and liraglutide — here is what peptide researchers need to know.
Survodutide Phase 3: dual GLP-1/glucagon agonist cuts visceral fat by 34% and liver fat by 63%
Boehringer Ingelheim and Zealand Pharma's survodutide demonstrated 34% visceral fat reduction and 63% liver fat reduction in Phase 3 trials, strengthening the case for dual GLP-1/glucagon agonism in cardiometabolic disease.
FDA approves orforglipron (Foundayo): first oral GLP-1 agonist for obesity marks shift in peptide therapeutics
The FDA has approved orforglipron under the brand name Foundayo, making it the first oral GLP-1 receptor agonist approved for obesity. The approval transforms the peptide therapeutic landscape by eliminating the need for injections.
Retatrutide TRIUMPH-4 Phase 3: triple agonist delivers 26.5% weight loss and significant knee osteoarthritis pain relief
Eli Lilly's retatrutide achieved 26.5% mean weight loss and significantly reduced knee osteoarthritis pain in the Phase 3 TRIUMPH-4 trial, marking the first successful obesity drug trial to demonstrate concurrent osteoarthritis benefit.
Roche reports positive Phase II results for petrelintide in obesity: amylin analog advances to late-stage trials
Roche's amylin analog petrelintide shows promising weight loss in Phase II, positioning it alongside cagrilintide as next-generation amylin-based therapeutics move toward the clinic.
Ecnoglutide Phase 3 results published in The Lancet: biased GLP-1 receptor agonist shows significant weight loss in obesity trial
A multicentre randomised Phase 3 trial of ecnoglutide, published in The Lancet, demonstrates the potential of biased GLP-1 receptor agonism as a differentiated approach to obesity treatment.
VK2735 Phase 2 VENTURE trial: Viking Therapeutics' dual GIP/GLP-1 agonist shows up to 14.7% weight loss in 13-week study
The Phase 2 VENTURE trial of VK2735, a subcutaneous dual GIP/GLP-1 receptor agonist from Viking Therapeutics, demonstrated dose-dependent weight loss of up to 14.7% at 13 weeks in adults with obesity. Results were published in a peer-reviewed PubMed-indexed journal, adding to the growing body of evidence for next-generation multi-receptor agonists in obesity treatment.
NICE recommends tirzepatide (Mounjaro) for obesity on the NHS: what researchers need to know about TA1026
NICE TA1026: tirzepatide for obesity — eligibility, review points, and what this UK regulatory milestone means for peptide research.
MHRA warns of pulmonary aspiration risk with GLP-1 and dual GIP/GLP-1 receptor agonists before anaesthesia
UK regulator strengthens guidance on GLP-1 agonists and anaesthesia: what peptide researchers need to know about delayed gastric emptying and aspiration risk.
MHRA warns of very rare NAION risk with semaglutide: UK regulator adds vision-loss precautions to Wegovy, Ozempic and Rybelsus
The UK MHRA has published a Drug Safety Update warning that semaglutide may very rarely be associated with non-arteritic anterior ischaemic optic neuropathy (NAION), a condition that can cause sudden vision loss. The EMA's pharmacovigilance committee is also reviewing the signal.
FDA Pharmacy Compounding Advisory Committee to review BPC-157, TB-500 and thymosin peptides: what peptide researchers need to know
The US FDA's PCAC will evaluate whether BPC-157, TB-500, thymosin alpha-1 and other popular research peptides remain on the 503A bulk substances list — a decision that could reshape the global research peptide supply chain
FDA clarifies compounding policy as GLP-1 shortage formally resolves: what it means for peptide researchers
With the FDA declaring an end to the semaglutide and tirzepatide shortages, compounding pharmacies must cease production. The policy shift has ripple effects for the broader research peptide market.
FDA requests removal of suicidal ideation boxed warning from GLP-1 receptor agonists
After a multi-year review, the US FDA concluded there is no causal link between GLP-1 receptor agonists and suicidal thoughts or behaviours, and has asked manufacturers to remove the boxed warning.
Danuglipron Phase 2b results published: Pfizer's oral GLP-1 shows up to 12.9% weight loss but high discontinuation rates
Pfizer's oral small-molecule GLP-1 receptor agonist danuglipron demonstrated dose-dependent weight loss up to 12.9% in a Phase 2b trial, but nearly 38% of participants discontinued due to adverse events.
CagriSema REDEFINE-1 results: Novo Nordisk's dual amylin/GLP-1 combination achieves 22.7% weight loss in Phase 3
Novo Nordisk's CagriSema (cagrilintide + semaglutide) delivered a 22.7% mean weight reduction in the REDEFINE-1 Phase 3 trial, but fell short of expectations for superiority over semaglutide alone.
SURMOUNT-5: Tirzepatide outperforms semaglutide in first head-to-head obesity trial published in NEJM
Eli Lilly's dual GIP/GLP-1 agonist tirzepatide demonstrated superior weight loss compared to semaglutide in the landmark direct-comparison SURMOUNT-5 trial, results published in the New England Journal of Medicine.
Retatrutide Phase 3 TRIUMPH-1 results: Eli Lilly's triple-agonist delivers powerful weight loss in pivotal obesity trial
Eli Lilly has announced top-line results from the first pivotal Phase 3 trial of retatrutide, a GLP-1/GIP/glucagon triple agonist, in adults with obesity. The drug's mechanism — targeting three incretin pathways simultaneously — positions it as a potential next-generation therapy beyond tirzepatide.
MariTide Phase 2 obesity data presented at ADA 2025: monthly GIP/GLP-1 antagonist-agonist shows sustained weight loss
Amgen's MariTide (maridebart cafraglutide) demonstrated up to 20% weight loss at 52 weeks in a Phase 2 obesity trial, with a durable monthly dosing profile.
Pemvidutide Phase 2b MASH results published in The Lancet: dual GLP-1/glucagon agonist shows fibrosis improvement
The GLP-1/glucagon dual agonist pemvidutide met its primary endpoint in a Phase 2b trial for metabolic dysfunction-associated steatohepatitis, published in The Lancet.
Orforglipron Phase 3 ACHIEVE-1 results published in NEJM: oral GLP-1 agonist matches injectable weight loss
The first Phase 3 data for an oral GLP-1 receptor agonist show 12–15% weight loss at 36 weeks, positioning orforglipron as a potential tablet alternative to injectable semaglutide and tirzepatide.
MHRA tightens guidance on research-peptide labelling
New wording clarifies that "not for human consumption" must appear on the primary label, not just the certificate.